Compass Therapeutics, Inc.: Form 10-Q for the period ended Jun 30, 2020
Filed with the SEC on Aug 13, 2020 and accepted by EDGAR at Aug 13, 2020, 18:57 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2020-04-01 to 2020-06-30 | $3.0m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2020-01-01 to 2020-06-30 | $6.6m | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2020-04-01 to 2020-06-30 | −$5.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2020-01-01 to 2020-06-30 | −$10.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2020-04-01 to 2020-06-30 | $242.0k | us-gaap:InterestExpense |
| Interest expense | 6 months2020-01-01 to 2020-06-30 | $518.0k | us-gaap:InterestExpense |
| Income tax | 3 months2020-04-01 to 2020-06-30 | $16.0k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2020-01-01 to 2020-06-30 | $32.0k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-04-01 to 2020-06-30 | −$5.6m | us-gaap:NetIncomeLoss |
| Net income | 6 months2020-01-01 to 2020-06-30 | −$12.0m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2020-04-01 to 2020-06-30 | −$0.41 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2020-01-01 to 2020-06-30 | −$1.16 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2020-01-01 to 2020-06-30 | −$13.1m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2020-01-01 to 2020-06-30 | $16.0k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2020-06-30 | $65.4m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-06-30 | $67.3m | us-gaap:AssetsCurrent |
| Total assets | At period end2020-06-30 | $70.4m | us-gaap:Assets |
| Current liabilities | At period end2020-06-30 | $11.6m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2020-06-30 | $17.2m | us-gaap:Liabilities |
| Long-term debt | At period end2020-06-30 | $5.6m | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2020-06-30 | $7.5m | us-gaap:LongTermDebtCurrent |
| Shareholders' equity | At period end2020-06-30 | $53.3m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001564590-20-039951. Last ingested by Listed: Oct 24, 2026, 15:07 ET. Listed shows no prices and gives no investment advice.